Danish Biotech Weekly – Week 21

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, Gubra announced phase I results regarding a potential anti-obesity medication, several companies announced their first quarter results and some got their price targets updated.

8 of the 20 listed, Danish biotech companies have published news the past week. 13 of the companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Fluoguide AB continues to be the best performing stock this year.

Company news the past week

Ascendis Pharma

No news the past week


No news the past week


No news the past week

CS Medica

CS MEDICA A/S’s CANNASEN® Pain Patch receives approval from Israel’s Ministry of Health and is set to debut as the first-ever OTC product with CBD in Israel (Link)

CS Medica published its Q2 2022/2023 report (Link)


No news the past week

Evaxion Biotech

No news the past week


ExpreS2ion announces financial results for the first quarter 2023 (Link)


No news the past week


EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma (Link)

Updated price targets: JP Morgan cuts its price target to 3200 DKK from 3400 DKK, and H.C. Wainwright raised its price target to $47 from $46 for the ADR shares.


Phase 1 trial results from a novel long acting NPY2-receptor agonist in partnership between Gubra A/S and Boehringer Ingelheim presented on European Congress on Obesity (Link)

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No news the past week


No news the past week

Scandion Oncology

Scandion Oncology will publish its Q1 2023 interim report on Friday May 26

SynAct Pharma

SynAct Pharma Appoints Björn Westberg As CFO (Link)


Sale of shares by majority shareholder in relation to terms for obtaining debt financing from Denmark’s Export and Investment Fund (EIFO) (Link)

ViroGates grants warrants to Denmark’s Export and Investment Fund (EIFO) as the final step in fulfilling the requirements to obtain debt financing (Link)

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

Bank of America raised its price target to $12 from $6


No news the past week



The majority of the Danish Biotech stocks delivered good performance last week. The average return was 1.5%. Saniona rose 30% followed by Initiator Pharma A/S and Evaxion Biotech A/S even though none of the companies presented any news. On the other hand, Pila Pharma A/S and Scandion Oncology A/S and 2Curex AB became the worst performing Danish biotech stocks last week falling 12-13%. In the past year, most of the companies have delivered a negative return. However, there has been two major outliers that have delivered an outstanding share price performance. Saniona AB and Zealand Pharma A/S have risen 193-195%. Both Saniona and Zealand Pharma are working on obesity medicines, and the interest in the stocks is likely to have increased considerably following Novo Nordisk’s major success with Wegovy.

Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment

Overview of share price developments the past week, year-to-date and last twelve months


Selected cases

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from Nyemission.dk)
  • Nyheder – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.

Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Del indlægget på sociale media eller på email.